Search Results 731-740 of 17429 for alopecia

1. Study of Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer - Mayo Clinic

   ... alopecia or Grade 2 peripheral neuropathy prior to randomization. Patients who are not candidates for adjuvant chemotherapy or decline chemotherapy are ...

2. Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors - Mayo Clinic

   Patients should have improvement of any toxic effects of prior therapy (except alopecia, fatigue, and other non-reversible toxic effects such as neuropathy ...

3. Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation - Mayo Clinic

   (Subjects with residual Grade 1 toxicity, for example Grade 1 peripheral neuropathy or residual alopecia, are allowed with approval of the Medical Monitor), ...

4. Tucatinib and Trastuzumab for Patients with HER2-positive Metastatic Colorectal Cancer - Mayo Clinic

   Alopecia and neuropathy, which must have resolved to ≤ Grade 2;; Congestive heart failure (CHF), which must have been ≤ Grade 1 in severity at the time of ...

5. Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction - Mayo Clinic

   ... alopecia; Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; Note: patients not on antiretroviral ...

6. Retinal diseases - Symptoms and causes - Mayo Clinic

   Types · Retinal tear. · Retinal detachment. · Diabetic retinopathy. · Epiretinal membrane. · Macular hole. · Macular degeneration. · Retinitis pigmentosa.

7. A Study of AO-176 as Monotherapy Combinated with Bortezomib and Dexamethasone in Adults with Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   Resolution of prior therapy-related AEs (including immune-related AEs but excluding alopecia) to ≤ Grade 1 (except for Grade 2 peripheral neuropathy) per CTCAE ...

8. A Study to Test Adding Pembrolizumab to Olaparib Alone as Therapy for Patients with Pancreatic Cancer That Has Spread with Inherited BRCA Mutations - Mayo Clinic

   ... alopecia. Zubrod performance status of 0-1. Patients must have a complete medical history and physical exam within 28 days prior to registration: Absolute ...

9. Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma - Mayo Clinic

   0) Grade -study baseline (except alopecia or neuropathy); Adequate organ function as defined by the following criteria: Serum aspartate transaminase (AST ...

10. Migraine Research Program - Videos

    View educational videos about migraine diagnosis, treatment and research from the Migraine Research Program at Mayo Clinic.